KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Assets (2018 - 2025)

Vir Biotechnology's Current Assets history spans 8 years, with the latest figure at $514.1 million for Q4 2025.

  • For Q4 2025, Current Assets fell 50.69% year-over-year to $514.1 million; the TTM value through Dec 2025 reached $514.1 million, down 50.69%, while the annual FY2025 figure was $514.1 million, 50.69% down from the prior year.
  • Current Assets for Q4 2025 was $514.1 million at Vir Biotechnology, down from $545.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $2.6 billion in Q1 2022 and bottomed at $514.1 million in Q4 2025.
  • The 5-year median for Current Assets is $1.2 billion (2024), against an average of $1.5 billion.
  • The largest annual shift saw Current Assets skyrocketed 165.37% in 2022 before it plummeted 50.69% in 2025.
  • A 5-year view of Current Assets shows it stood at $1.6 billion in 2021, then skyrocketed by 61.19% to $2.5 billion in 2022, then plummeted by 36.95% to $1.6 billion in 2023, then tumbled by 34.36% to $1.0 billion in 2024, then tumbled by 50.69% to $514.1 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Current Assets are $514.1 million (Q4 2025), $545.7 million (Q3 2025), and $735.7 million (Q2 2025).